OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

Nov 11, 2022 8:38am EST

OncoSec Announces Reverse Stock Split

Nov 08, 2022 1:22pm EST

OncoSec Announces Pipeline Prioritization and Workforce Reduction

Oct 04, 2022 5:23pm EDT

Novel pre-clinical results regarding OncoSec’s intratumoral electroporation platform were highlighted as Editor’s Pick in Molecular Cancer Research

Jun 24, 2022 8:00am EDT

OncoSec Receives Triple Negative Breast Cancer Foundation’s Vanguard Award for Excellence in Oncology Research

May 23, 2022 8:00am EDT

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

Apr 29, 2022 8:00am EDT

OncoSec Announces Appointment of George Chi as Chief Financial Officer

Feb 22, 2022 5:59pm EST

OncoSec Announces Changes to its Board of Directors

Dec 17, 2021 9:09am EST

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

Nov 02, 2021 8:00am EDT

OncoSec Provides Business Update

Oct 20, 2021 4:02pm EDT